Back to top

Image: Bigstock

The Zacks Analyst Blog Highlights: Accenture, Raytheon, Becton, Dickinson and Co, Boeing and Gilead Sciences

Read MoreHide Full Article

For Immediate Release

Chicago, IL – November 30, 2021 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Accenture plc (ACN - Free Report) , Raytheon Technologies Corporation (RTX - Free Report) , Becton, Dickinson and Company (BDX - Free Report) , The Boeing Company (BA - Free Report) and Gilead Sciences, Inc. (GILD - Free Report) .

Here are highlights from Monday’s Analyst Blog:

Top Analyst Reports for Accenture, Raytheon and Becton Dickinson

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Accenture, Raytheon, and Becton, Dickinson and Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Shares of Accenture have outperformed the Zacks Consulting industry over the past year (+48.1% vs. +47.8%). The Zacks analyst believes that Accenture has been steadily gaining traction in its outsourcing as well as consulting businesses backed by high demand for services that can improve operating efficiencies and save costs.

Considering the growing need for cloud-based applications and software, Accenture’s investments in this space are likely to propel long-term growth. Stiff competition and pricing pressure, however, remain as the major headwinds. Higher talent costs due to a competitive talent market has also been hurting Accenture’s prospects.

(You can read the full research report on Accenture here >>>)

Raytheon shares have gained +18.7% in the year to date period against the Zacks Aerospace - Defense industry’s gain of +7.3%. The Zacks analyst believes that merger related synergies and solid order growth are likely to continue aiding Raytheon Technologies.

RTN’s management continues to expect both domestic and international program growth to remain robust for its defense business in the quarters ahead. The SEAKR Engineering acquisition is expected to boost this missile-maker’s space-based capabilities. Continued air travel restrictions due to the ongoing pandemic, however, continues to weigh on the operating results of RTN’s Aerospace business.

(You can read the full research report on Raytheon here >>>)

Shares of Becton, Dickinson have gained +1.6% in the past six months against the Zacks Dental Supplies industry’s gain of +2.4%, however, things seem to be improving for it. The Zacks analyst is encouraged by regulatory approvals, a plethora of launches as well as a slew of strategic acquisitions that the company has inked.

The FDA’s Emergency Use Authorization for Becton, Dickinson’s Veritor At-Home COVID-19 Test and the 510(k) clearance for expanded indications for Rotarex Rotational Excisional Atherectomy System, bode well for the long term. Stiff competition and persistent forex woes, however, remain as the major headwinds.

(You can read the full research report on Becton, Dickinson here >>>)

Other noteworthy reports we are featuring today include Boeing and Gilead Sciences.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339                                                                        


Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.